Although the deregulated expression of CASC2 in cancer enhances its tumorigenic properties, however, the literature evidence limits current knowledge on the pathophysiological implications and the roles of CASC2, and its interplay with miR-21 in the pathology of gliomas [20]. The gene discussed is CASC2; the disease is central nervous system cancer.